SCHEMBL24253831

SCHEMBL24253831

O=C1CCCC2(CCN(c3cc(-n4cccn4)nc(N4CCOCC4)n3)CC2)N1c1ccc(F)c(F)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.40
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDM6B O15054 4/20 0.40
PIK3CA P42336 5/20 0.36
MTOR P42345 1/20 0.36
JAK3 P52333 1/20 0.36
NTRK2 Q16620 1/20 0.36
CAMK2A Q9UQM7 1/20 0.36
PIK3CB P42338 5/20 0.34
PIK3CD O00329 4/20 0.33
PIK3CG P48736 1/20 0.33
RAD51 Q06609 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
ATR Q13535 1/20 0.33
ATRIP Q8WXE1 1/20 0.33
KMT2A Q03164 1/20 0.32
AKT1 P31749 1/20 0.32
GBA1 P04062 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30423987 1.00 HTT (0.40) HTTLMNASMN1; SMN2KDM6BPIK3CA
SCHEMBL30423904 0.88 KDM6B (0.40) KDM6BHCRTR1HCRTR2
SCHEMBL24253862 0.88 KDM6B (0.40) KDM6BHCRTR1HCRTR2
SCHEMBL30424036 0.87 RAD51 (0.33) PIK3CAMTORPIK3CBPIK3CDRAD51
SCHEMBL26307936 0.87 RAD51 (0.33) PIK3CAMTORPIK3CBPIK3CDRAD51
SCHEMBL24253622 0.86 KDM6B (0.39) KDM6BHCRTR1HCRTR2
SCHEMBL24253939 0.85 KDM6B (0.39) KDM6BHCRTR1HCRTR2
SCHEMBL30423911 0.85 KDM6B (0.39) KDM6BHCRTR1HCRTR2
SCHEMBL24253942 0.85 KDM6B (0.39) KDM6BGBA1HCRTR1HCRTR2
SCHEMBL24253944 0.85 KDM6B (0.39) KDM6BHCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 HTT 1346/4885LMNA 2975/4885SMN1; SMN2 2877/4885
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 HTT 1346/4885LMNA 2975/4885SMN1; SMN2 2877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.